{"pub": "businessinsider", "url": "https://businesstimes.com.sg/consumer/roche-extends-spark-offer-again-as-regulatory-review-drags-on", "downloaded_at": "2019-09-30 06:37:20.649784+00:00", "title": "Roche extends Spark offer again as regulatory review drags on", "language": "en", "text": "Roche extended its offer to buy Spark Therapeutics on Monday, this time until Oct 30, as US and British regulators continue to scrutinize the Swiss drugmaker's US$4.3 billion oft-delayed bid to swallow the US gene therapy specialist.\n\n[ZURICH] Roche extended its offer to buy Spark Therapeutics on Monday, this time until Oct 30, as US and British regulators continue to scrutinize the Swiss drugmaker's US$4.3 billion oft-delayed bid to swallow the US gene therapy specialist.\n\nThe terms and conditions remain unchanged for the deal, which analysts have said may be hung up on competition concerns over what a combination would mean for the very competitive market for hemophilia A treatments. Roche has declined to comment on what is holding back the US Federal Trade Commission from signing off on the transaction.\n\nREUTERS", "description": ": THE BUSINESS TIMES Consumer - [ZURICH] Roche extended its offer to buy Spark Therapeutics on Monday, this time until Oct 30, as US and British regulators continue to scrutinize the Swiss drugmaker's US$4.3 billion oft-delayed bid to swallow the US gene therapy specialist. . Read more at The Business Times.", "authors": [], "top_image": "https://www.businesstimes.com.sg/sites/default/files/styles/article_img_retina/public/image/2019/09/30/AK_roche_3009.jpg?itok=48MskDtQ", "published_at": "2019-09-30"}